Furthermore, to interrogate whether the generation of antigen-specific cells was affected by treatment, splenocytes isolated from mice treated with ganetespib, with and without anti-CTLA4, were stimulated ex vivo with either DMSO (control), gp100, or p15E peptides (MHC I restricted peptides expressed by the MC38/gp100 tumor), and IFN-gamma production was assessed by ELISPOT. This evidence concerns the gene CTLA4 and neoplasm.